BACKGROUND: Adverse events related to drugs occur frequently among inpatients, and many of these events are preventable. However, few data are available on adverse drug events among outpatients. We conducted a study to determine the rates, types, severity, and preventability of such events among outpatients and to identify preventive strategies. METHODS: We performed a prospective cohort study, including a survey of patients and a chart review, at four adult primary care practices in Boston (two hospital-based and two community-based), involving a total of 1202 outpatients who received at least one prescription during a four-week period. Prescriptions were computerized at two of the practices and handwritten at the other two. RESULTS: Of the 661 patients who responded to the survey (response rate, 55 percent), 162 had adverse drug events (25 percent; 95 percent confidence interval, 20 to 29 percent), with a total of 181 events (27 per 100 patients). Twenty-four of the events (13 percent) were serious, 51 (28 percent) were ameliorable, and 20 (11 percent) were preventable. Of the 51 ameliorable events, 32 (63 percent) were attributed to the physician's failure to respond to medication-related symptoms and 19 (37 percent) to the patient's failure to inform the physician of the symptoms. The medication classes most frequently involved in adverse drug events were selective serotonin-reuptake inhibitors (10 percent), beta-blockers (9 percent), angiotensin-converting-enzyme inhibitors (8 percent), and nonsteroidal antiinflammatory agents (8 percent). On multivariate analysis, only the number of medications taken was significantly associated with adverse events. CONCLUSIONS: Adverse events related to drugs are common in primary care, and many are preventable or ameliorable. Monitoring for and acting on symptoms are important. Improving communication between outpatients and providers may help prevent adverse events related to drugs. Copyright 2003 Massachusetts Medical Society
BACKGROUND: Adverse events related to drugs occur frequently among inpatients, and many of these events are preventable. However, few data are available on adverse drug events among outpatients. We conducted a study to determine the rates, types, severity, and preventability of such events among outpatients and to identify preventive strategies. METHODS: We performed a prospective cohort study, including a survey of patients and a chart review, at four adult primary care practices in Boston (two hospital-based and two community-based), involving a total of 1202 outpatients who received at least one prescription during a four-week period. Prescriptions were computerized at two of the practices and handwritten at the other two. RESULTS: Of the 661 patients who responded to the survey (response rate, 55 percent), 162 had adverse drug events (25 percent; 95 percent confidence interval, 20 to 29 percent), with a total of 181 events (27 per 100 patients). Twenty-four of the events (13 percent) were serious, 51 (28 percent) were ameliorable, and 20 (11 percent) were preventable. Of the 51 ameliorable events, 32 (63 percent) were attributed to the physician's failure to respond to medication-related symptoms and 19 (37 percent) to the patient's failure to inform the physician of the symptoms. The medication classes most frequently involved in adverse drug events were selective serotonin-reuptake inhibitors (10 percent), beta-blockers (9 percent), angiotensin-converting-enzyme inhibitors (8 percent), and nonsteroidal antiinflammatory agents (8 percent). On multivariate analysis, only the number of medications taken was significantly associated with adverse events. CONCLUSIONS: Adverse events related to drugs are common in primary care, and many are preventable or ameliorable. Monitoring for and acting on symptoms are important. Improving communication between outpatients and providers may help prevent adverse events related to drugs. Copyright 2003 Massachusetts Medical Society
Authors: M Victoria Martínez Jiménez; Macarena Flores Dorado; José Espejo Guerrero; Pedro Jiménez Vicente; Fernando Martínez Martínez; Elena Bernabé Muñoz Journal: Aten Primaria Date: 2011-09-19 Impact factor: 1.137
Authors: Eliz Markowitz; Elmer V Bernstam; Jorge Herskovic; Jiajie Zhang; Ben Shneiderman; Catherine Plaisant; Todd R Johnson Journal: AMIA Annu Symp Proc Date: 2011-10-22
Authors: F van Stiphout; J E F Zwart-van Rijkom; J Versmissen; H Koffijberg; J E C M Aarts; I H van der Sijs; T van Gelder; R A de Man; C B Roes; A C G Egberts; E W M T Ter Braak Journal: Br J Clin Pharmacol Date: 2018-03-23 Impact factor: 4.335
Authors: Andrew D Auerbach; Sunil Kripalani; Eduard E Vasilevskis; Neil Sehgal; Peter K Lindenauer; Joshua P Metlay; Grant Fletcher; Gregory W Ruhnke; Scott A Flanders; Christopher Kim; Mark V Williams; Larissa Thomas; Vernon Giang; Shoshana J Herzig; Kanan Patel; W John Boscardin; Edmondo J Robinson; Jeffrey L Schnipper Journal: JAMA Intern Med Date: 2016-04 Impact factor: 21.873